Wacrs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Wacrs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Wacrs Today - Breaking & Trending Today

FY2023 EPS Estimates for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Lifted by HC Wainwright

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) – Analysts at HC Wainwright upped their FY2023 earnings estimates for Aclaris Therapeutics in a report released on Monday, January 22nd. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of ($1.65) per share for the year, up from their previous forecast of […] ....

United States , Stifel Nicolaus , Leerink Partnrs , William Blair , Contract Research , Corton Capital Inc , Royal Bank , Aclaris Therapeutics Inc , Aclaris Therapeutics , Free Report , Aclaris Therapeutic , Get Free Report , Therapeutics Stock Down , Aclaris Therapeutics Daily , Nasdaq Acrs , Earnings Estimates , Hc Wainwright ,

Aclaris Therapeutics (NASDAQ:ACRS) Downgraded to "Neutral" at HC Wainwright

Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) was downgraded by research analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research note issued to investors on Monday, Marketbeat Ratings reports. A number of other equities research analysts also recently weighed in on the company. William Blair downgraded Aclaris Therapeutics from […] ....

United States , William Blair , Stifel Nicolaus , Leerink Partnrs , Aclaris Therapeutics Company Profile , Contract Research , Corton Capital Inc , Aclaris Therapeutics Inc , Royal Bank , Aclaris Therapeutics , Get Free Report , Marketbeat Ratings , Aclaris Therapeutics Daily , Nasdaq Acrs , Hc Wainwright ,

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of "Moderate Buy" from Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has received a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective […] ....

Los Angeles , United States , Stifel Nicolaus , Joseph Monahan , Leerink Partnrs , Contract Research , Sg Americas Securities , Securities Exchange Commission , Aclaris Therapeutics Inc , Los Angeles Capital Management , York Mellon Corp , Hsbc Holdings , Cantor Fitzgerald , Westwood Holdings Group Inc , Aclaris Therapeutics , Get Free Report , Exchange Commission , New York Mellon Corp , Holdings Group , Therapeutics Trading Down , Get Free , Aclaris Therapeutics Daily , Nasdaq Acrs ,

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average […] ....

United States , Joseph Monahan , Stifel Nicolaus , William Blair , Vanguard Group Inc , Aclaris Therapeutics Inc , Contract Research , Cantor Fitzgerald , Jacobs Levy Equity Management Inc , Corton Capital Inc , Blackstone Inc , Aclaris Therapeutics , Get Free Report , Levy Equity Management , Trexquant Investment , Get Free , Aclaris Therapeutics Daily , Nasdaq Acrs ,